WHAT IS CLAIMED IS:

1. A method comprising the steps of:

(a) subjecting harvested Dupilumab to affinity chromatography;

(b) subjecting said Dupilumab pooled from eluate of step (a) to viral inactivation at a pH from about 3 to about 4 and then adjusting the pH to from about 5 to about 8;

(c) subjecting said Dupilumab pooled from step (b) to mixed-mode chromatography;

(d) subjecting said Dupilumab pooled from step (c) to anion exchange chromatography in flowthrough mode; and

(e) subjecting said Dupilumab pooled from flowthrough fractions of step (d) to virus retentive filtration to produce Dupilumab.

2. The method of claim 1, further comprising a harvest pre-treatment step prior to step (a).

3. The method of claim 2, wherein said harvest pre-treatment step includes adjusting said Dupilumab to a transient pH level from about 4 to 5.5.

4. The method of claim 1, further comprising subjecting said Dupilumab to ultrafiltration and diafiltration (UF/DF) after step (e).

5. The method of claim 4, wherein said UF/DF includes a diafiltration buffer having a pH between 4.0 and 4.5.

6. The method of claim 4, wherein a concentrated Dupilumab pool following UF/DF has a pH of about 5.3.

7. The method of claim 4, wherein said UF/DF includes a diafiltration buffer comprising between about 4 mM acetate and about 6 mM acetate.

8. The method of claim 1, wherein said affinity chromatography is Protein A chromatography.

9. The method of claim 8, wherein a Protein A resin is selected from the group consisting of MabSelect PrismA, MabSelect SuRe, MabSelect SuRe LX, MabSelect, MabSelect SuRe pcc, MabSelect Xtra, rProtein A Sepharose, ProSep HC, ProSep Ultra, ProSep Ultra Plus, MabCapture, and Amsphere A3.

10. The method of claim 8, wherein a Protein A resin is selected that is capable of receiving a load at a concentration above 55 g/L.

11. The method of claim 8, wherein a Protein A column load pH is between 6 and 8.

12. The method of claim 8, wherein a Protein A wash buffer is selected for removing host cell proteins bound to said Dupilumab.

13. The method of claim 12, wherein said Protein A wash buffer has a pH between about 5 and about 9.

14. The method of claim 12, wherein said Protein A wash buffer has a pH corresponding to the pI of an HCP of concern.

15. The method of claim 12, wherein said Protein A wash buffer comprises arginine, potassium sorbate, sodium benzoate, guanidine, Tris, isopropanol, urea, sodium carbonate, or a combination thereof.

16. The method of claim 12, wherein said Protein A wash buffer comprises about 450 mM arginine.

17. The method of claim 1, wherein a mixed-mode chromatography resin is selected from the group consisting of Capto Adhere, Capto Adhere ImpRes, Capto MMC, PPA HyperCel, HEA HyperCel, MEP HyperCel, MBI HyperCel, CMM HyperCel, Capto Core 700, Nuvia C Prime, Toyo Pearl MX Trp 650M, and Eshmuno HCX.

18. The method of claim 1, wherein said mixed-mode chromatography is operated in flowthrough mode or bind-and-elute mode.

19. The method of claim 1, wherein said Dupilumab comprises three heavy chain complementarity determining region (HCDR) sequences comprising SEQ ID NOs: 3, 4, and 5, and three light chain complementarity determining region (LCDR) sequences comprising SEQ ID NOs: 6, 7, and 8.

20. The method of claim 1, wherein said Dupilumab comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2.

21. A method comprising the steps of:

(a) culturing cells expressing Dupilumab;

(b) subjecting said cells to transient pH levels from about 4 to 5.5, then raising pH levels to from about 5.5 to 6.5;

(c) harvesting said cells by centrifugation to separate cell debris from clarified media comprising said Dupilumab;

(d) subjecting said clarified media to affinity chromatography;

(e) subjecting said Dupilumab pooled from eluate of step (d) to viral inactivation at a pH from about 3 to about 4 and then adjusting the pH to from about 5 to about 8;

(f) subjecting said Dupilumab pooled from step (e) to mixed-mode chromatography in flowthrough mode;

(g) subjecting said Dupilumab pooled from flowthrough fractions of step (f) to anion exchange chromatography in flowthrough mode; and

(h) subjecting said Dupilumab pooled from flowthrough fractions of step (g) to virus retentive filtration to produce Dupilumab.

22. The method of claim 21, further comprising subjecting said Dupilumab to ultrafiltration and diafiltration (UF/DF) after step (h).

23. The method of claim 21, wherein said affinity chromatography is Protein A chromatography.

24. The method of claim 23, wherein a Protein A resin is selected from the group consisting of MabSelect PrismA, MabSelect SuRe, MabSelect SuRe LX, MabSelect, MabSelect SuRe pcc, MabSelect Xtra, rProtein A Sepharose, ProSep HC, ProSep Ultra, ProSep Ultra Plus, MabCapture, and AmsphereA3.

25. The method of claim 21, wherein a Protein A wash buffer is selected for removing host cell proteins bound to said Dupilumab.

26. The method of claim 21, wherein a mixed-mode chromatography resin is selected from the group consisting of Capto Adhere, Capto Adhere ImpRes, Capto MMC, PPA HyperCel, HEA HyperCel, MEP HyperCel, MBI HyperCel, CMM HyperCel, Capto Core 700, Nuvia C Prime, Toyo Pearl MX Trp 650M, and Eshmuno HCX.

27. The method of claim 21, wherein an anion exchange resin is selected from the group consisting of Q Sepharose Fast Flow, Poros 50PI, Poros 50HQ, Capto Q Impres, Capto DEAE, Toyopearl QAE-550, Toyopearl DEAE-650, Toyopearl GigaCap Q-650, Fractogel EMD TMAE Hicap, Sartobind STIC PA nano, Sartobind Q nano, CUNO BioCap, and XOHC.

28. The method of claim 21, further comprising passing said Dupilumab through a LifeAssure filter after the viral inactivation of step (e) and prior to the mixed-mode chromatography of step (f).

29. The method of claim 22, wherein said UF/DF step comprises a membrane filter device selected from the group consisting of Pellicon 2, Pellicon 3 cassettes with 10 kD, 30 kD or 50 kD membranes, Kvick 10 kD, 30 kD or 50 kD membrane cassettes, and Centramate and Centrasette 10 kD, 30 kD or 50 kD cassettes.

30. The method of claim 22, wherein said UF/DF step does not include addition of arginine.

31. The method of claim 21, wherein said Dupilumab comprises three heavy chain complementarity determining region (HCDR) sequences comprising SEQ ID NOs: 3, 4, and 5, and three light chain complementarity determining region (LCDR) sequences comprising SEQ ID NOs: 6, 7, and 8.

32. The method of claim 21, wherein said Dupilumab comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2.

33. A method comprising the steps of:

(a) subjecting a harvested antibody to affinity chromatography;

(b) subjecting said antibody pooled from eluate of step (a) to viral inactivation at a pH from about 3 to about 4 and then adjusting the pH to from about 5 to about 8;

(c) subjecting said antibody pooled from step (b) to mixed-mode chromatography;

(d) subjecting said antibody pooled from step (c) to anion exchange chromatography in flowthrough mode; and

(e) subjecting said antibody pooled from flowthrough fractions of step (d) to virus retentive filtration to produce an anti-IL4Rα antibody.

34. The method of claim 33, further comprising a harvest pre-treatment step prior to step (a).

35. The method of claim 34, wherein said harvest pre-treatment step includes adjusting said antibody to a transient pH level from about 4 to 5.5.

36. The method of claim 33, further comprising subjecting said antibody to ultrafiltration and diafiltration (UF/DF) after step (e).

37. The method of claim 36, wherein said UF/DF includes a diafiltration buffer having a pH between 4.0 and 4.5.

38. The method of claim 36, wherein a concentrated antibody pool following UF/DF has a pH of about 5.3.

39. The method of claim 36, wherein said UF/DF includes a diafiltration buffer comprising between about 4 mM acetate and about 6 mM acetate.

40. The method of claim 33, wherein said affinity chromatography is Protein A chromatography.

41. The method of claim 40, wherein a Protein A resin is selected from the group consisting of MabSelect PrismA, MabSelect SuRe, MabSelect SuRe LX, MabSelect, MabSelect SuRe pcc, MabSelect Xtra, rProtein A Sepharose, ProSep HC, ProSep Ultra, ProSep Ultra Plus, MabCapture, and Amsphere A3.

42. The method of claim 40, wherein a Protein A resin is selected that is capable of receiving a load at a concentration above 55 g/L.

43. The method of claim 40, wherein a Protein A column load pH is between 6 and 8.

44. The method of claim 40, wherein a Protein A wash buffer is selected for removing host cell proteins bound to said anti-IL-4Rα antibody.

45. The method of claim 44, wherein said Protein A wash buffer has a pH between about 5 and about 9.

46. The method of claim 44, wherein said Protein A wash buffer has a pH corresponding to the pI of an HCP of concern.

47. The method of claim 44, wherein said Protein A wash buffer comprises arginine, potassium sorbate, sodium benzoate, guanidine, Tris, isopropanol, urea, sodium carbonate, or a combination thereof.

48. The method of claim 44, wherein said Protein A wash buffer comprises about 450 mM arginine.

49. The method of claim 33, wherein a mixed-mode chromatography resin is selected from the group consisting of Capto Adhere, Capto Adhere ImpRes, Capto MMC, PPA HyperCel, HEA HyperCel, MEP HyperCel, MBI HyperCel, CMM HyperCel, Capto Core 700, Nuvia C Prime, Toyo Pearl MX Trp 650M, and Eshmuno HCX.

50. The method of claim 33, wherein said mixed-mode chromatography is operated in flowthrough mode or bind-and-elute mode.

51. The method of claim 33, wherein said anti-IL-4Rα antibody comprises three heavy chain complementarity determining region (HCDR) sequences comprising SEQ ID NOs: 3, 4, and 5, and three light chain complementarity determining region (LCDR) sequences comprising SEQ ID NOs: 6, 7, and 8.

52. The method of claim 33, wherein said anti-IL-4Rα antibody comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2.

53. The method of claim 33, wherein said anti-IL-4Rα antibody is Dupilumab.